Therapeutic targeting of the pro-tumoral IL-25-ILC2 axis via antibody-mediated blockade reduced intratumoral M-MDSCs and enhanced adaptive T cell IFNγ expression, leading to reduced CRC burden in mice. The gene discussed is IL25; the disease is colorectal carcinoma.